Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent P2-VP8 with Rotarix or RV3-BB in Infants
NCT04344054Phase 2Completed
- Sponsor
- PATH
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of trivalent P2-VP8 subunit rotavirus vaccine in rotavirus infection, sponsored by PATH. Primary endpoints: Serum anti-rotavirus IgA antibody concentration, Immediate adverse events and 3 more. Started Feb 2021; status: completed.
02
Drugs
trivalent P2-VP8 subunit rotavirus vaccine
03
Conditions
rotavirus infection
Beyond the preview
Go deeper on NCT04344054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04344054.